Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$1.01
-2.9%		$1.10
$0.55
▼
$3.83
$98.90M1.77550,979 shs506,859 shs
ImmuCell Corporation stock logo
ICCC
ImmuCell
$10.05
-7.8%		$10.51
$4.52
▼
$12.10
$98.61M0.5419,725 shs92,025 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$2.01
+1.9%		$2.36
$1.12
▼
$3.96
$102.44M0.3391,374 shs170,740 shs
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$3.44
-1.1%		$3.61
$3.18
▼
$10.00
$26M1.4591,081 shs57,160 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
0.00%-7.96%+2.97%-8.77%-14.75%
ImmuCell Corporation stock logo
ICCC
ImmuCell
-0.73%-1.09%-7.00%+22.20%+66.92%
Rafael Holdings, Inc. stock logo
RFL
Rafael
+2.01%+2.27%-15.80%+56.88%+21.56%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
0.00%+1.16%-6.95%-33.33%-63.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$1.01
-2.9%		$1.10
$0.55
▼
$3.83
$98.90M1.77550,979 shs506,859 shs
ImmuCell Corporation stock logo
ICCC
ImmuCell
$10.05
-7.8%		$10.51
$4.52
▼
$12.10
$98.61M0.5419,725 shs92,025 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$2.01
+1.9%		$2.36
$1.12
▼
$3.96
$102.44M0.3391,374 shs170,740 shs
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$3.44
-1.1%		$3.61
$3.18
▼
$10.00
$26M1.4591,081 shs57,160 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
0.00%-7.96%+2.97%-8.77%-14.75%
ImmuCell Corporation stock logo
ICCC
ImmuCell
-0.73%-1.09%-7.00%+22.20%+66.92%
Rafael Holdings, Inc. stock logo
RFL
Rafael
+2.01%+2.27%-15.80%+56.88%+21.56%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
0.00%+1.16%-6.95%-33.33%-63.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2.50
Moderate Buy$3.33230.03% Upside
ImmuCell Corporation stock logo
ICCC
ImmuCell
1.00
SellN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
1.00
SellN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest TAOX, RFL, ICCC, and CGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/2/2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/22/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
5/28/2026
Rafael Holdings, Inc. stock logo
RFL
Rafael
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/A$0.35 per shareN/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
$27.64M3.29$0.18 per share56.54$2.99 per share3.36
Rafael Holdings, Inc. stock logo
RFL
Rafael
$920K113.44N/AN/A$1.91 per share1.05
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$300K85.66N/AN/A$2.83 per share1.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$23.49M-$0.17N/AN/AN/AN/A-50.17%-40.22%N/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
-$1.04M-$0.06125.64N/AN/A2.57%2.75%1.79%N/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
-$30.52M-$0.68N/AN/AN/A-3,321.74%-41.27%-35.32%10/28/2026 (Estimated)
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
-$28.74M-$13.28N/AN/AN/A-2,153.97%-116.74%-93.67%N/A

Latest TAOX, RFL, ICCC, and CGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
$0.05$0.20+$0.15$0.20$5.40 million$7.19 million
8/13/2026Q2 2026
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A-$1.83N/A-$1.83N/A$0.09 million
8/6/2026Q2 2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.0633-$0.04+$0.0233-$0.04$5.00 millionN/A
5/14/2026Q1 2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
$0.05$0.21+$0.16$0.21$5.40 million$10.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/AN/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
N/AN/AN/AN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/AN/AN/AN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/A
7.03
5.92
ImmuCell Corporation stock logo
ICCC
ImmuCell
0.24
4.82
2.60
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/A
3.16
3.14
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A
27.39
27.39

Institutional Ownership

CompanyInstitutional Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
43.35%
ImmuCell Corporation stock logo
ICCC
ImmuCell
13.47%
Rafael Holdings, Inc. stock logo
RFL
Rafael
11.30%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
10.34%

Insider Ownership

CompanyInsider Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
11.11%
ImmuCell Corporation stock logo
ICCC
ImmuCell
5.70%
Rafael Holdings, Inc. stock logo
RFL
Rafael
32.90%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2095.09 million84.53 millionNot Optionable
ImmuCell Corporation stock logo
ICCC
ImmuCell
709.05 million8.53 millionNot Optionable
Rafael Holdings, Inc. stock logo
RFL
Rafael
2052.00 million34.89 millionOptionable
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
47.47 million7.27 millionN/A

Recent News About These Companies

TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor
July 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-appoints-bittensor-investor-and-author-mark-jeffrey-as-advisor-302820337.html
TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI
June 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-set-to-join-the-russell-microcap-index-as-a-leading-public-gateway-to-decentralized-ai-302801330.html
TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation
November 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-and-yuma-asset-management-to-host-livestream-on-x-bittensor-tao-and-deai-innovation-302618425.html
Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys
November 11, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tradr-set-to-debut-etfs-targeting-bloom-energy-celestica-nano-nuclear-and-synopsys-302611818.html
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds
November 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-announces-initial-750-000-investment-in-yuma-asset-managements-subnet-funds-302603960.html
TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency
October 20, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-raises-bittensor-tao-holdings-to-over-54-000-tokens-largest-publicly-traded-holder-of-top-decentralized-ai-cryptocurrency-302589032.html
TAO Synergies Announces $11 Million Private Placement
October 13, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-announces-11-million-private-placement-302582503.html
TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)
September 22, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-launches-the-tao-daily-the-premier-media-platform-for-all-things-bittensor-tao-302562601.html
TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event
September 8, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-digital-assets-advisor-james-altucher-speaks-at-googles-planet-scale-consumer-ai-event-302548971.html
TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today
July 1, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-formerly-synaptogenix-begins-trading-under-new-nasdaq-stock-symbol-taox-effective-at-market-open-today-302495716.html
Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy
June 26, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-announces-name-change-to-tao-synergies-and-new-ticker-symbol-taox-for-alignment-with-ai-focused-crypto-treasury-strategy-302491852.html
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN Austin
June 26, 2025  |  kxan.comK
Synaptogenix begins TAO acquisition as part of crypto treasury strategy
June 26, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/synaptogenix-begins-tao-acquisition-as-part-of-crypto-treasury-strategy-93CH-4144284
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLA
June 26, 2025  |  ktla.comK
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking
June 24, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-announces-initial-tao-acquisition-under-crypto-treasury-strategy-appoints-bitgo-as-custodian-and-commences-yield-generation-through-staking-302489342.html
Synaptogenix Unveils TAO-Focused Crypto Treasury Plan
June 10, 2025  |  livebitcoinnews.comL
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token
June 9, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-appoints-crypto-expert-to-lead-digital-asset-treasury-strategy-focused-exclusively-on-top-valued-ai-token-302476176.html
Synaptogenix Inc Ordinary Shares
January 3, 2025  |  morningstar.comM
Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
December 20, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-board-of-directors-forms-special-committee-to-explore-value-creation-opportunities-utilizing-balance-sheet-strength-302336765.html
Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary
October 7, 2024  |  benzinga.comhttps://www.benzinga.com/quote/SNPX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cognition Therapeutics stock logo

Cognition Therapeutics NASDAQ:CGTX

$1.01 -0.03 (-2.88%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 +0.01 (+1.49%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

ImmuCell stock logo

ImmuCell NASDAQ:ICCC

$10.05 -0.85 (-7.80%)
Closing price 04:00 PM Eastern
Extended Trading
$10.06 +0.00 (+0.05%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Rafael stock logo

Rafael NYSE:RFL

$2.01 +0.04 (+1.88%)
Closing price 03:59 PM Eastern
Extended Trading
$1.93 -0.08 (-3.89%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Synaptogenix stock logo

Synaptogenix NASDAQ:TAOX

$3.44 -0.04 (-1.15%)
Closing price 04:00 PM Eastern
Extended Trading
$3.46 +0.02 (+0.58%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas